• Publications
  • Influence
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
TLDR
Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticogulant activity.
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
TLDR
The data suggest that dabigatran etexilate is a promising novel oral DTI with predictable PK and PD characteristics and good tolerability, and further investigation of dabig atran e Texilate for the treatment and prophylaxis of patients with arterial and venous thromboembolic disorders, acute coronary syndromes and other medical conditions is warranted.
Idarucizumab for Dabigatran Reversal.
TLDR
Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes and normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes.
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
TLDR
Exposure to dabigatran is increased by renal impairment and correlates with the severity of renal dysfunction, and a decrease in the dose and/or an increase in the administration interval in these patients may be appropriate.
Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate
TLDR
Results obtained so far show that dabigatran etexilate is well tolerated and effective in the treatment and prevention of thromboembolic events.
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
TLDR
In vitro experiments confirmed that dabigatran etexilate is metabolized primarily by esterases and that cytochrome P450 plays no relevant role, and suggest that pharmacologically active concentrations of dabig atran are readily achieved after p.o.v. administration and that the potential for clinically relevant interactions between dabIGatran and drugs metabolized by cytochrom P450 is low.
Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
TLDR
Dabigatran demonstrated reproducible and predictable pharmacokinetic and pharmacodynamic characteristics, together with a good safety profile, when administered to healthy elderly subjects and the effects of pantoprazole coadministration on the bioavailability were considered acceptable.
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
TLDR
Dabigatran plasma concentrations, activated partial thromboplastin time, D-dimer, urinary 11-dehydrothromboxane B(2) (DTB2), and liver function were measured at baseline and at 1, 2, 4, 8, and 12 weeks and the significance of the increase of DTB2 concentrations in dabig atran-treated patients needs resolution.
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
TLDR
Oral administration of dabigatran etexilate, commenced early in the postoperative period, was effective and safe across a range of doses and further optimization of the efficacy/safety balance will be addressed in future studies.
Unusual cardioactive peptide (CCAP) from pericardial organs of the shore crab Carcinus maenas.
TLDR
An unusual crustacean cardioactive peptide from the pericardial organs of the shore crab Carcinus maenas has been purified to homogeneity by a two-step reversed-phase HPLC procedure and confirmed by chemical synthesis of the C-terminally amidated and nonamidated forms of the peptide.
...
1
2
3
4
5
...